Well-designed prospective clinical trials, for patients rigorously selected by HER2-positive tumors and, possibly, stratified by tumor location, are warranted to confirm the benefit of adding anti-HER2-targeted agents to chemotherapy in advanced disease. This evidence concerns the gene ERBB2 and neoplasm.